Transmedics Group Inc (NASDAQ: TMDX)’s stock price has gone rise by 7.45 in comparison to its previous close of 72.62, however, the company has experienced a 4.75% increase in its stock price over the last five trading days. Seeking Alpha reported 2024-03-19 that FY2023: TransMedics’ revenues up 159%, profitability improves, breakeven could be on the horizon. Potential 2x top-line growth medium term in the U.S. alone. TransMedics’ Organ Care System (OCS) could drive transplant volumes by expanding the donor pool through increased utilization of marginal (including DCD) organs. As the only FDA-approved multi-organ platform, TransMedics faces relatively limited competition at the moment and looks well positioned to establish a market leading position.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
TMDX has 36-month beta value of 1.98. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TMDX is 31.48M, and currently, short sellers hold a 17.18% ratio of that float. The average trading volume of TMDX on April 03, 2024 was 636.92K shares.
TMDX’s Market Performance
The stock of Transmedics Group Inc (TMDX) has seen a 4.75% increase in the past week, with a -10.29% drop in the past month, and a 1.60% gain in the past quarter. The volatility ratio for the week is 4.78%, and the volatility levels for the past 30 days are at 4.86% for TMDX. The simple moving average for the past 20 days is 0.83% for TMDX’s stock, with a 8.32% simple moving average for the past 200 days.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with Piper Sandler repeating the rating for TMDX by listing it as a “Overweight.” The predicted price for TMDX in the upcoming period, according to Piper Sandler is $95 based on the research report published on March 28, 2024 of the current year 2024.
JP Morgan gave a rating of “Overweight” to TMDX, setting the target price at $48 in the report published on August 02nd of the previous year.
TMDX Trading at -5.76% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.68% of loss for the given period.
Volatility was left at 4.86%, however, over the last 30 days, the volatility rate increased by 4.78%, as shares sank -3.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -9.68% lower at present.
During the last 5 trading sessions, TMDX rose by +6.83%, which changed the moving average for the period of 200-days by -0.08% in comparison to the 20-day moving average, which settled at $77.25. In addition, Transmedics Group Inc saw -1.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Gordon Stephen, who sale 15,000 shares at the price of $74.01 back on Apr 01 ’24. After this action, Gordon Stephen now owns 23,299 shares of Transmedics Group Inc, valued at $1,110,150 using the latest closing price.
Gordon Stephen, the Chief Financial Officer of Transmedics Group Inc, sale 1,903 shares at $87.63 during a trade that took place back on Mar 08 ’24, which means that Gordon Stephen is holding 23,299 shares at $166,760 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- -0.12 for the present operating margin
- 0.64 for the gross margin
The net margin for Transmedics Group Inc stands at -0.1. The total capital return value is set at -0.04. Equity return is now at value -15.42, with -5.09 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.79 points at debt to capital in total, while cash flow to debt ratio is standing at -0.03. The debt to equity ratio resting at 3.7. The interest coverage ratio of the stock is -2.66.
Currently, EBITDA for the company is 8.76 million with net debt to EBITDA at -7.11. When we switch over and look at the enterprise to sales, we see a ratio of 11.02. The receivables turnover for the company is 3.8for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.30.
Conclusion
To put it simply, Transmedics Group Inc (TMDX) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
